aluates Reports

$ 0.0

Automative

Global Microbiome Drugs Market Research Report 2025

Published Date: August 2025

Report Code: QYRE-Auto-1H9391

Global Microbiome Drugs Market Insights and Forecast to 2028

BUY CHAPTERS

Global Microbiome Drugs Market Research Report 2025

Code: QYRE-Auto-1H9391

Report

August 2025

Pages:105

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Seres Therapeutics

Assembly Biosciences

Synthetic Biologics

PureTech

Synlogic

Enterome BioScience

4D Pharma

Second Genome

Rebiotix

Metabiomics

Ritter Pharmaceuticals

Symberix

OpenBiome

Azitra

Finch Therapeutics

Ferring

C3 Jian

MicroBiome Therapeutics LLC

Symbiotix Biotherapies

Vedanta Biosciences

Metabogen

Microbiome Drugs Market Size

The global market for Microbiome Drugs was valued at US$ 568 million in the year 2024 and is projected to reach a revised size of US$ 3296 million by 2031, growing at a CAGR of 30.1% during the forecast period.

Microbiome Drugs Market

Microbiome Drugs refer to a new class of therapeutic agents developed based on human commensal microbiota and their metabolites. These include live biotherapeutic products (LBPs), microbiota-derived metabolites, synthetic microbial formulations, and microbiome-targeted small molecule drugs. By modulating the host’s microecological environment—such as the gut, skin, or respiratory tract—these therapies aim to restore immune balance, regulate metabolism, and treat a broad spectrum of diseases including infectious conditions, inflammatory bowel diseases, metabolic disorders, neuropsychiatric illnesses, and cancers. As breakthroughs in microbiome science and synthetic biology continue to accelerate, microbiome drugs are emerging as a core pillar of precision medicine—transforming treatment paradigms from "killing microbes" to "leveraging microbes" for systemic therapeutic benefit.

As the concept of precision medicine continues to evolve globally, microbiome drugs are rapidly emerging as a new strategic frontier in biopharmaceutical innovation. Regulatory authorities in multiple countries have established dedicated review pathways for live microbiome-based products, accelerating clinical translation. According to annual reports from companies several Phase III candidates are approaching commercialization, signaling an imminent market inflection point. Meanwhile, advances in synthetic biology are enabling engineered microbial therapeutics with stable expression platforms, transforming microbiota therapies from fecal transplants into standardized pharmaceuticals. With chronic diseases, immune disorders, and oncology driving demand, global investment and R&D resources are converging toward this transformative sector.

Despite their disruptive potential, microbiome drugs remain in the early adoption phase, facing both technological and regulatory uncertainty. Real-world data reveal high inter-patient variability and inconsistent efficacy in some early-stage products, posing challenges for clinical standardization. Manufacturing, cold-chain logistics, and quality control requirements for live biotherapeutics impose high technical barriers, particularly in scaling up production. In addition, reimbursement frameworks and clinical funding mechanisms are still underdeveloped in many regions, slowing broad market penetration in the short term.

On the demand side, deeper insights into host-microbiome interactions are driving a shift from “supplemental probiotics” to “interventional prescription drugs.” Physicians are increasingly open to microbiome-based therapies, especially for patients with refractory Clostridium difficile infections, ulcerative colitis, autism spectrum disorders, and type 2 diabetes. Leading hospitals are partnering with pharma companies to conduct joint development and real-world studies, fostering a transition from academic trials to routine clinical use. As more candidates reach critical trial milestones, microbiome drugs are poised to establish a distinct and high-potential segment within the global prescription drug market.

This report aims to provide a comprehensive presentation of the global market for Microbiome Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Microbiome Drugs.

The Microbiome Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Microbiome Drugs market comprehensively. Regional market sizes, concerning products by Type, by Symptom, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Microbiome Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Symptom, and by regions.

Market Segmentation

Scope of Microbiome Drugs Market Report

Report Metric	Details
Report Name	Microbiome Drugs Market
Accounted market size in year	US$ 568 million
Forecasted market size in 2031	US$ 3296 million
CAGR	30.1%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Oral Dosage Form Enteric Capsules
Segment by Symptom	Gastrointestinal Disorders Autoimmune Disorders Diabetes Cancer Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Finch Therapeutics, PureTech, Synlogic, Enterome BioScience, 4D Pharma, Second Genome, Ferring, C3 Jian, Rebiotix, MicroBiome Therapeutics LLC, Metabiomics, Ritter Pharmaceuticals, Symberix, OpenBiome, Azitra, Symbiotix Biotherapies, Vedanta Biosciences, Metabogen
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Symptom, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Microbiome Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Symptom, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Microbiome Drugs Market growing?

Ans: The Microbiome Drugs Market witnessing a CAGR of 30.1% during the forecast period 2025-2031.

What is the Microbiome Drugs Market size in 2031?

Ans: The Microbiome Drugs Market size in 2031 will be US$ 3296 million.

Who are the main players in the Microbiome Drugs Market report?

Ans: The main players in the Microbiome Drugs Market are Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Finch Therapeutics, PureTech, Synlogic, Enterome BioScience, 4D Pharma, Second Genome, Ferring, C3 Jian, Rebiotix, MicroBiome Therapeutics LLC, Metabiomics, Ritter Pharmaceuticals, Symberix, OpenBiome, Azitra, Symbiotix Biotherapies, Vedanta Biosciences, Metabogen

What are the Type segmentation covered in the Microbiome Drugs Market report?

Ans: The Types covered in the Microbiome Drugs Market report are Oral Dosage Form, Enteric Capsules

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Microbiome Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Oral Dosage Form

1.2.3 Enteric Capsules

1.3 Market by Symptom

1.3.1 Global Microbiome Drugs Market Growth by Symptom: 2020 VS 2024 VS 2031

1.3.2 Gastrointestinal Disorders

1.3.3 Autoimmune Disorders

1.3.4 Diabetes

1.3.5 Cancer

1.3.6 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Microbiome Drugs Market Perspective (2020-2031)

2.2 Global Microbiome Drugs Growth Trends by Region

2.2.1 Global Microbiome Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Microbiome Drugs Historic Market Size by Region (2020-2025)

2.2.3 Microbiome Drugs Forecasted Market Size by Region (2026-2031)

2.3 Microbiome Drugs Market Dynamics

2.3.1 Microbiome Drugs Industry Trends

2.3.2 Microbiome Drugs Market Drivers

2.3.3 Microbiome Drugs Market Challenges

2.3.4 Microbiome Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Microbiome Drugs Players by Revenue

3.1.1 Global Top Microbiome Drugs Players by Revenue (2020-2025)

3.1.2 Global Microbiome Drugs Revenue Market Share by Players (2020-2025)

3.2 Global Top Microbiome Drugs Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Microbiome Drugs Revenue

3.4 Global Microbiome Drugs Market Concentration Ratio

3.4.1 Global Microbiome Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Microbiome Drugs Revenue in 2024

3.5 Global Key Players of Microbiome Drugs Head office and Area Served

3.6 Global Key Players of Microbiome Drugs, Product and Application

3.7 Global Key Players of Microbiome Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Microbiome Drugs Breakdown Data by Type

4.1 Global Microbiome Drugs Historic Market Size by Type (2020-2025)

4.2 Global Microbiome Drugs Forecasted Market Size by Type (2026-2031)

5 Microbiome Drugs Breakdown Data by Symptom

5.1 Global Microbiome Drugs Historic Market Size by Symptom (2020-2025)

5.2 Global Microbiome Drugs Forecasted Market Size by Symptom (2026-2031)

6 North America

6.1 North America Microbiome Drugs Market Size (2020-2031)

6.2 North America Microbiome Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Microbiome Drugs Market Size by Country (2020-2025)

6.4 North America Microbiome Drugs Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Microbiome Drugs Market Size (2020-2031)

7.2 Europe Microbiome Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Microbiome Drugs Market Size by Country (2020-2025)

7.4 Europe Microbiome Drugs Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Microbiome Drugs Market Size (2020-2031)

8.2 Asia-Pacific Microbiome Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Microbiome Drugs Market Size by Region (2020-2025)

8.4 Asia-Pacific Microbiome Drugs Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Microbiome Drugs Market Size (2020-2031)

9.2 Latin America Microbiome Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Microbiome Drugs Market Size by Country (2020-2025)

9.4 Latin America Microbiome Drugs Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Microbiome Drugs Market Size (2020-2031)

10.2 Middle East & Africa Microbiome Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Microbiome Drugs Market Size by Country (2020-2025)

10.4 Middle East & Africa Microbiome Drugs Market Size by Country (2026-2031)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Seres Therapeutics

11.1.1 Seres Therapeutics Company Details

11.1.2 Seres Therapeutics Business Overview

11.1.3 Seres Therapeutics Microbiome Drugs Introduction

11.1.4 Seres Therapeutics Revenue in Microbiome Drugs Business (2020-2025)

11.1.5 Seres Therapeutics Recent Development

11.2 Assembly Biosciences

11.2.1 Assembly Biosciences Company Details

11.2.2 Assembly Biosciences Business Overview

11.2.3 Assembly Biosciences Microbiome Drugs Introduction

11.2.4 Assembly Biosciences Revenue in Microbiome Drugs Business (2020-2025)

11.2.5 Assembly Biosciences Recent Development

11.3 Synthetic Biologics

11.3.1 Synthetic Biologics Company Details

11.3.2 Synthetic Biologics Business Overview

11.3.3 Synthetic Biologics Microbiome Drugs Introduction

11.3.4 Synthetic Biologics Revenue in Microbiome Drugs Business (2020-2025)

11.3.5 Synthetic Biologics Recent Development

11.4 Finch Therapeutics

11.4.1 Finch Therapeutics Company Details

11.4.2 Finch Therapeutics Business Overview

11.4.3 Finch Therapeutics Microbiome Drugs Introduction

11.4.4 Finch Therapeutics Revenue in Microbiome Drugs Business (2020-2025)

11.4.5 Finch Therapeutics Recent Development

11.5 PureTech

11.5.1 PureTech Company Details

11.5.2 PureTech Business Overview

11.5.3 PureTech Microbiome Drugs Introduction

11.5.4 PureTech Revenue in Microbiome Drugs Business (2020-2025)

11.5.5 PureTech Recent Development

11.6 Synlogic

11.6.1 Synlogic Company Details

11.6.2 Synlogic Business Overview

11.6.3 Synlogic Microbiome Drugs Introduction

11.6.4 Synlogic Revenue in Microbiome Drugs Business (2020-2025)

11.6.5 Synlogic Recent Development

11.7 Enterome BioScience

11.7.1 Enterome BioScience Company Details

11.7.2 Enterome BioScience Business Overview

11.7.3 Enterome BioScience Microbiome Drugs Introduction

11.7.4 Enterome BioScience Revenue in Microbiome Drugs Business (2020-2025)

11.7.5 Enterome BioScience Recent Development

11.8 4D Pharma

11.8.1 4D Pharma Company Details

11.8.2 4D Pharma Business Overview

11.8.3 4D Pharma Microbiome Drugs Introduction

11.8.4 4D Pharma Revenue in Microbiome Drugs Business (2020-2025)

11.8.5 4D Pharma Recent Development

11.9 Second Genome

11.9.1 Second Genome Company Details

11.9.2 Second Genome Business Overview

11.9.3 Second Genome Microbiome Drugs Introduction

11.9.4 Second Genome Revenue in Microbiome Drugs Business (2020-2025)

11.9.5 Second Genome Recent Development

11.10 Ferring

11.10.1 Ferring Company Details

11.10.2 Ferring Business Overview

11.10.3 Ferring Microbiome Drugs Introduction

11.10.4 Ferring Revenue in Microbiome Drugs Business (2020-2025)

11.10.5 Ferring Recent Development

11.11 C3 Jian

11.11.1 C3 Jian Company Details

11.11.2 C3 Jian Business Overview

11.11.3 C3 Jian Microbiome Drugs Introduction

11.11.4 C3 Jian Revenue in Microbiome Drugs Business (2020-2025)

11.11.5 C3 Jian Recent Development

11.12 Rebiotix

11.12.1 Rebiotix Company Details

11.12.2 Rebiotix Business Overview

11.12.3 Rebiotix Microbiome Drugs Introduction

11.12.4 Rebiotix Revenue in Microbiome Drugs Business (2020-2025)

11.12.5 Rebiotix Recent Development

11.13 MicroBiome Therapeutics LLC

11.13.1 MicroBiome Therapeutics LLC Company Details

11.13.2 MicroBiome Therapeutics LLC Business Overview

11.13.3 MicroBiome Therapeutics LLC Microbiome Drugs Introduction

11.13.4 MicroBiome Therapeutics LLC Revenue in Microbiome Drugs Business (2020-2025)

11.13.5 MicroBiome Therapeutics LLC Recent Development

11.14 Metabiomics

11.14.1 Metabiomics Company Details

11.14.2 Metabiomics Business Overview

11.14.3 Metabiomics Microbiome Drugs Introduction

11.14.4 Metabiomics Revenue in Microbiome Drugs Business (2020-2025)

11.14.5 Metabiomics Recent Development

11.15 Ritter Pharmaceuticals

11.15.1 Ritter Pharmaceuticals Company Details

11.15.2 Ritter Pharmaceuticals Business Overview

11.15.3 Ritter Pharmaceuticals Microbiome Drugs Introduction

11.15.4 Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2020-2025)

11.15.5 Ritter Pharmaceuticals Recent Development

11.16 Symberix

11.16.1 Symberix Company Details

11.16.2 Symberix Business Overview

11.16.3 Symberix Microbiome Drugs Introduction

11.16.4 Symberix Revenue in Microbiome Drugs Business (2020-2025)

11.16.5 Symberix Recent Development

11.17 OpenBiome

11.17.1 OpenBiome Company Details

11.17.2 OpenBiome Business Overview

11.17.3 OpenBiome Microbiome Drugs Introduction

11.17.4 OpenBiome Revenue in Microbiome Drugs Business (2020-2025)

11.17.5 OpenBiome Recent Development

11.18 Azitra

11.18.1 Azitra Company Details

11.18.2 Azitra Business Overview

11.18.3 Azitra Microbiome Drugs Introduction

11.18.4 Azitra Revenue in Microbiome Drugs Business (2020-2025)

11.18.5 Azitra Recent Development

11.19 Symbiotix Biotherapies

11.19.1 Symbiotix Biotherapies Company Details

11.19.2 Symbiotix Biotherapies Business Overview

11.19.3 Symbiotix Biotherapies Microbiome Drugs Introduction

11.19.4 Symbiotix Biotherapies Revenue in Microbiome Drugs Business (2020-2025)

11.19.5 Symbiotix Biotherapies Recent Development

11.20 Vedanta Biosciences

11.20.1 Vedanta Biosciences Company Details

11.20.2 Vedanta Biosciences Business Overview

11.20.3 Vedanta Biosciences Microbiome Drugs Introduction

11.20.4 Vedanta Biosciences Revenue in Microbiome Drugs Business (2020-2025)

11.20.5 Vedanta Biosciences Recent Development

11.21 Metabogen

11.21.1 Metabogen Company Details

11.21.2 Metabogen Business Overview

11.21.3 Metabogen Microbiome Drugs Introduction

11.21.4 Metabogen Revenue in Microbiome Drugs Business (2020-2025)

11.21.5 Metabogen Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Seres Therapeutics

Assembly Biosciences

Synthetic Biologics

PureTech

Synlogic

Enterome BioScience

4D Pharma

Second Genome

Rebiotix

Metabiomics

Ritter Pharmaceuticals

Symberix

OpenBiome

Azitra

Finch Therapeutics

Ferring

C3 Jian

MicroBiome Therapeutics LLC

Symbiotix Biotherapies

Vedanta Biosciences

Metabogen

List of Tables

Table 1. Global Microbiome Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Oral Dosage Form

Table 3. Key Players of Enteric Capsules

Table 4. Global Microbiome Drugs Market Size Growth by Symptom (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Microbiome Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Microbiome Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Microbiome Drugs Market Share by Region (2020-2025)

Table 8. Global Microbiome Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Microbiome Drugs Market Share by Region (2026-2031)

Table 10. Microbiome Drugs Market Trends

Table 11. Microbiome Drugs Market Drivers

Table 12. Microbiome Drugs Market Challenges

Table 13. Microbiome Drugs Market Restraints

Table 14. Global Microbiome Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Microbiome Drugs Market Share by Players (2020-2025)

Table 16. Global Top Microbiome Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Drugs as of 2024)

Table 17. Ranking of Global Top Microbiome Drugs Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Microbiome Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Microbiome Drugs, Headquarters and Area Served

Table 20. Global Key Players of Microbiome Drugs, Product and Application

Table 21. Global Key Players of Microbiome Drugs, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Microbiome Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Microbiome Drugs Revenue Market Share by Type (2020-2025)

Table 25. Global Microbiome Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Microbiome Drugs Revenue Market Share by Type (2026-2031)

Table 27. Global Microbiome Drugs Market Size by Symptom (2020-2025) & (US$ Million)

Table 28. Global Microbiome Drugs Revenue Market Share by Symptom (2020-2025)

Table 29. Global Microbiome Drugs Forecasted Market Size by Symptom (2026-2031) & (US$ Million)

Table 30. Global Microbiome Drugs Revenue Market Share by Symptom (2026-2031)

Table 31. North America Microbiome Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Microbiome Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Microbiome Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Microbiome Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Microbiome Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Microbiome Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Microbiome Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Microbiome Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Microbiome Drugs Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Microbiome Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Microbiome Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Microbiome Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Microbiome Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Microbiome Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Microbiome Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 46. Seres Therapeutics Company Details

Table 47. Seres Therapeutics Business Overview

Table 48. Seres Therapeutics Microbiome Drugs Product

Table 49. Seres Therapeutics Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 50. Seres Therapeutics Recent Development

Table 51. Assembly Biosciences Company Details

Table 52. Assembly Biosciences Business Overview

Table 53. Assembly Biosciences Microbiome Drugs Product

Table 54. Assembly Biosciences Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 55. Assembly Biosciences Recent Development

Table 56. Synthetic Biologics Company Details

Table 57. Synthetic Biologics Business Overview

Table 58. Synthetic Biologics Microbiome Drugs Product

Table 59. Synthetic Biologics Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 60. Synthetic Biologics Recent Development

Table 61. Finch Therapeutics Company Details

Table 62. Finch Therapeutics Business Overview

Table 63. Finch Therapeutics Microbiome Drugs Product

Table 64. Finch Therapeutics Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 65. Finch Therapeutics Recent Development

Table 66. PureTech Company Details

Table 67. PureTech Business Overview

Table 68. PureTech Microbiome Drugs Product

Table 69. PureTech Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 70. PureTech Recent Development

Table 71. Synlogic Company Details

Table 72. Synlogic Business Overview

Table 73. Synlogic Microbiome Drugs Product

Table 74. Synlogic Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 75. Synlogic Recent Development

Table 76. Enterome BioScience Company Details

Table 77. Enterome BioScience Business Overview

Table 78. Enterome BioScience Microbiome Drugs Product

Table 79. Enterome BioScience Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 80. Enterome BioScience Recent Development

Table 81. 4D Pharma Company Details

Table 82. 4D Pharma Business Overview

Table 83. 4D Pharma Microbiome Drugs Product

Table 84. 4D Pharma Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 85. 4D Pharma Recent Development

Table 86. Second Genome Company Details

Table 87. Second Genome Business Overview

Table 88. Second Genome Microbiome Drugs Product

Table 89. Second Genome Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 90. Second Genome Recent Development

Table 91. Ferring Company Details

Table 92. Ferring Business Overview

Table 93. Ferring Microbiome Drugs Product

Table 94. Ferring Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 95. Ferring Recent Development

Table 96. C3 Jian Company Details

Table 97. C3 Jian Business Overview

Table 98. C3 Jian Microbiome Drugs Product

Table 99. C3 Jian Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 100. C3 Jian Recent Development

Table 101. Rebiotix Company Details

Table 102. Rebiotix Business Overview

Table 103. Rebiotix Microbiome Drugs Product

Table 104. Rebiotix Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 105. Rebiotix Recent Development

Table 106. MicroBiome Therapeutics LLC Company Details

Table 107. MicroBiome Therapeutics LLC Business Overview

Table 108. MicroBiome Therapeutics LLC Microbiome Drugs Product

Table 109. MicroBiome Therapeutics LLC Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 110. MicroBiome Therapeutics LLC Recent Development

Table 111. Metabiomics Company Details

Table 112. Metabiomics Business Overview

Table 113. Metabiomics Microbiome Drugs Product

Table 114. Metabiomics Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 115. Metabiomics Recent Development

Table 116. Ritter Pharmaceuticals Company Details

Table 117. Ritter Pharmaceuticals Business Overview

Table 118. Ritter Pharmaceuticals Microbiome Drugs Product

Table 119. Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 120. Ritter Pharmaceuticals Recent Development

Table 121. Symberix Company Details

Table 122. Symberix Business Overview

Table 123. Symberix Microbiome Drugs Product

Table 124. Symberix Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 125. Symberix Recent Development

Table 126. OpenBiome Company Details

Table 127. OpenBiome Business Overview

Table 128. OpenBiome Microbiome Drugs Product

Table 129. OpenBiome Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 130. OpenBiome Recent Development

Table 131. Azitra Company Details

Table 132. Azitra Business Overview

Table 133. Azitra Microbiome Drugs Product

Table 134. Azitra Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 135. Azitra Recent Development

Table 136. Symbiotix Biotherapies Company Details

Table 137. Symbiotix Biotherapies Business Overview

Table 138. Symbiotix Biotherapies Microbiome Drugs Product

Table 139. Symbiotix Biotherapies Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 140. Symbiotix Biotherapies Recent Development

Table 141. Vedanta Biosciences Company Details

Table 142. Vedanta Biosciences Business Overview

Table 143. Vedanta Biosciences Microbiome Drugs Product

Table 144. Vedanta Biosciences Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 145. Vedanta Biosciences Recent Development

Table 146. Metabogen Company Details

Table 147. Metabogen Business Overview

Table 148. Metabogen Microbiome Drugs Product

Table 149. Metabogen Revenue in Microbiome Drugs Business (2020-2025) & (US$ Million)

Table 150. Metabogen Recent Development

Table 151. Research Programs/Design for This Report

Table 152. Key Data Information from Secondary Sources

Table 153. Key Data Information from Primary Sources

Table 154. Authors List of This Report

List of Figures

Figure 1. Microbiome Drugs Picture

Figure 2. Global Microbiome Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Microbiome Drugs Market Share by Type: 2024 VS 2031

Figure 4. Oral Dosage Form Features

Figure 5. Enteric Capsules Features

Figure 6. Global Microbiome Drugs Market Size by Symptom (2020-2031) & (US$ Million)

Figure 7. Global Microbiome Drugs Market Share by Symptom: 2024 VS 2031

Figure 8. Gastrointestinal Disorders Case Studies

Figure 9. Autoimmune Disorders Case Studies

Figure 10. Diabetes Case Studies

Figure 11. Cancer Case Studies

Figure 12. Others Case Studies

Figure 13. Microbiome Drugs Report Years Considered

Figure 14. Global Microbiome Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Microbiome Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Microbiome Drugs Market Share by Region: 2024 VS 2031

Figure 17. Global Microbiome Drugs Market Share by Players in 2024

Figure 18. Global Microbiome Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 19. The Top 10 and 5 Players Market Share by Microbiome Drugs Revenue in 2024

Figure 20. North America Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Microbiome Drugs Market Share by Country (2020-2031)

Figure 22. United States Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Microbiome Drugs Market Share by Country (2020-2031)

Figure 26. Germany Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Ireland Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Microbiome Drugs Market Share by Region (2020-2031)

Figure 34. China Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia & New Zealand Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Microbiome Drugs Market Share by Country (2020-2031)

Figure 42. Mexico Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Microbiome Drugs Market Share by Country (2020-2031)

Figure 46. Israel Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Microbiome Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Seres Therapeutics Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 50. Assembly Biosciences Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 51. Synthetic Biologics Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 52. Finch Therapeutics Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 53. PureTech Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 54. Synlogic Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 55. Enterome BioScience Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 56. 4D Pharma Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 57. Second Genome Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 58. Ferring Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 59. C3 Jian Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 60. Rebiotix Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 61. MicroBiome Therapeutics LLC Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 62. Metabiomics Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 63. Ritter Pharmaceuticals Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 64. Symberix Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 65. OpenBiome Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 66. Azitra Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 67. Symbiotix Biotherapies Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 68. Vedanta Biosciences Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 69. Metabogen Revenue Growth Rate in Microbiome Drugs Business (2020-2025)

Figure 70. Bottom-up and Top-down Approaches for This Report

Figure 71. Data Triangulation

Figure 72. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Human Microbiome Therapeutic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Microbiome Therapies Market Research Report 2024

Global Microbiome Sample Preparation Technology Market Research Report 2024

Microbiome Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Human Microbiome Modulators Market Insights Forecast to 2030

Global Human Microbiome Analysis Market Research Report 2024

Global Microbiome CDMO Market Research Report 2024

Global Microbiome Cosmetic Market Research Report 2025

Agriculture Microbiome Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Microbiomes Market Research Report 2024

Global Microbiome Cosmetic Product Market Research Report 2025

Crop Microbiome Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Medicinal Microbiology Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Human Microbiome Sequencing Services Market Research Report 2024

Global Microecological Drugs Market Research Report 2024

Antibiotics Active Pharmaceutical Ingredient API Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Microbiome Skincare Product Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Microbiome Therapeutics and Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Cancer Microbiome Market Research Report 2024

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-14Y6812

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-34O3983

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9V17601

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22C17047

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions